Lentiviral vectors for generating immune responses against human T Lymphotrophic Virus Type 1
AssigneeTheravectys
InventorsDeborah Revaud, Cecile Bauche
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions, methods, and uses employing lentiviral vector particles for induction of an immune response by administration to a human, wherein the lentiviral vector particles comprise a lentiviral vector, wherein the DNA of the lentiviral vector comprises a promoter directing expression of a HTLV-1 p12p30-Tax-HBZ fusion protein. The invention encompasses these vectors, methods of making the vectors, and methods of using them, including medicinal uses.
Claims12
A method for inducing an immune response comprising intramuscularly administering to a human a composition comprising lentiviral vector particles,
- wherein the lentiviral vector particles comprise a lentiviral vector;
- wherein DNA of the lentiviral vector comprises a promoter directing expression of a polypeptide comprising a HTLV-1 p12p30-Tax-HBZ fusion protein.
A composition comprising lentiviral vector particles for induction of an immune response by intramuscular administration to a human,
- wherein the lentiviral vector particles comprise a lentiviral vector;
- wherein the DNA of the lentiviral vector comprises a promoter directing expression of a polypeptide comprising a HTLV-1 p12p30-Tax-HBZ fusion protein.
Dependencies are inferred from the claim text.